The therapeutic potential of mTOR inhibitors in breast cancer

Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From BOLERO-2

(2016) Gabriel N. Hortobagyi et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeted therapies for ER+/HER2- metastatic breast cancer

(2015) Mutsuko Yamamoto-Ibusuki et al.   BMC Medicine

Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy

(2015) Carlos Acevedo-Gadea et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor

(2015) Kimberly Blackwell et al.   BREAST CANCER RESEARCH AND TREATMENT

A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma

(2015) Johanna C. Bendell et al.   CANCER

Rapamycin-induced G1 cell cycle arrest employs both TGF-β and Rb pathways

(2015) Amrita Chatterjee et al.   CANCER LETTERS

mTOR inhibitors counteract tamoxifen-induced activation of breast cancer stem cells

(2015) Govindasamy-Muralidharan Karthik et al.   CANCER LETTERS

Oral Ridaforolimus Plus Trastuzumab for Patients With HER2+ Trastuzumab-Refractory Metastatic Breast Cancer

(2015) Milton Seiler et al.   Clinical Breast Cancer

A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies

(2015) S. Gupta et al.   CLINICAL CANCER RESEARCH

S6 kinase signaling: tamoxifen response and prognostic indication in two breast cancer cohorts

(2015) J. Bostner et al.   ENDOCRINE-RELATED CANCER

Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours

(2015) S.A. Piha-Paul et al.   EUROPEAN JOURNAL OF CANCER

Blocking mammalian target of rapamycin alleviates bone cancer pain and morphine toleranceviaµ-opioid receptor

(2015) Zongming Jiang et al.   INTERNATIONAL JOURNAL OF CANCER

The Combination of Rapamycin and Resveratrol Blocks Autophagy and Induces Apoptosis in Breast Cancer Cells

(2015) Anya Alayev et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial

(2015) Sara A Hurvitz et al.   LANCET ONCOLOGY

AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

(2015) S. M. Guichard et al.   MOLECULAR CANCER THERAPEUTICS

mTORC1 directly phosphorylates and activates ERα upon estrogen stimulation

(2015) A Alayev et al.   ONCOGENE

Combined Use of Metformin and Everolimus Is Synergistic in the Treatment of Breast Cancer Cells

(2015) Yunshan Wang et al.   ONCOLOGY RESEARCH

Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines

(2015) Euphemia Y. Leung et al.   PLoS One

Validation of p27KIP1 expression levels as a candidate predictive biomarker of response to rapalogs in patient-derived breast tumor xenografts

(2015) Xiao-Fei Ding et al.   TUMOR BIOLOGY

AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis

(2015) Wenting Mi et al.   Oncotarget

Addition of rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic solid tumors: a pilot safety and effectiveness analysis in a small patient cohort

(2015) Kwan-Hwa Chi et al.   Oncotarget

Epithelial to mesenchymal transition is associated with rapamycin resistance

(2015) Ashley M. Holder et al.   Oncotarget

Lipin-1 regulates cancer cell phenotype and is a potential target to potentiate rapamycin treatment

(2015) Laura Brohée et al.   Oncotarget

Everolimus Plus Exemestane for the Treatment of Advanced Breast Cancer: A Review of Subanalyses from BOLERO-2

(2015) Gabriel N. Hortobagyi   NEOPLASIA

Tumor promoter-induced cellular senescence: cell cycle arrest followed by geroconversion

(2015) Olga V. Leontieva et al.   Oncotarget

Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention

(2015) Nicole M. Davis et al.   Oncotarget

GSK-3 as potential target for therapeutic intervention in cancer

(2015) James A. McCubrey et al.   Oncotarget

Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†

(2014) A. M. Gonzalez-Angulo et al.   ANNALS OF ONCOLOGY

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2

(2014) H. S. Rugo et al.   ANNALS OF ONCOLOGY

Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer

(2014) I. Treilleux et al.   ANNALS OF ONCOLOGY

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†

(2014) M. Piccart et al.   ANNALS OF ONCOLOGY

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)†

(2014) G. von Minckwitz et al.   ANNALS OF ONCOLOGY

Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer

(2014) Jasmeet Chadha Singh et al.   BREAST CANCER RESEARCH

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

(2014) Fabrice André et al.   LANCET ONCOLOGY

Clinical implications of recent studies using mTOR inhibitors to treat advanced hormone receptor-positive breast cancer

(2014) Francis Arena   Cancer Management and Research

Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

(2013) Denise A. Yardley et al.   ADVANCES IN THERAPY

A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure

(2013) Suleiman Massarweh et al.   BREAST CANCER RESEARCH AND TREATMENT

Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer

(2013) François Vaillant et al.   CANCER CELL

Health-related quality of life and disease symptoms in postmenopausal women with HR+, HER2−advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy

(2013) Mario Campone et al.   CURRENT MEDICAL RESEARCH AND OPINION

Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2

(2013) M. Gnant et al.   JNCI-Journal of the National Cancer Institute

Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2

(2013) Shinzaburo Noguchi et al.   Breast Cancer

Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures

(2012) Peter Kabos et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase II trial of temsirolimus in patients with metastatic breast cancer

(2012) Gini F. Fleming et al.   BREAST CANCER RESEARCH AND TREATMENT

Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study

(2012) Thomas Bachelot et al.   JOURNAL OF CLINICAL ONCOLOGY

Appropriate Design of Prospective Studies

(2012) Jung-Hye Choi et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

(2012) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial

(2012) Michael Untch et al.   LANCET ONCOLOGY

Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer

(2012) Gunter von Minckwitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy

(2011) Phuong K. Morrow et al.   JOURNAL OF CLINICAL ONCOLOGY

PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer

(2011) A. M. Gonzalez-Angulo et al.   MOLECULAR CANCER THERAPEUTICS

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer

(2010) Guy Jerusalem et al.   BREAST CANCER RESEARCH AND TREATMENT

Inhibition of Mammalian Target of Rapamycin Is Required for Optimal Antitumor Effect of HER2 Inhibitors against HER2-Overexpressing Cancer Cells

(2009) T. W. Miller et al.   CLINICAL CANCER RESEARCH

Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer

(2009) Jan C. Buckner et al.   INVESTIGATIONAL NEW DRUGS

Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer

(2009) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

Evaluating Temsirolimus Activity in Multiple Tumors: A Review of Clinical Trials

(2009) Janet E. Dancey et al.   SEMINARS IN ONCOLOGY

Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic Data

(2008) Chiaki Tanaka et al.   JOURNAL OF CLINICAL ONCOLOGY